CulineS., DrozJ.P.Chemotherapy in advanced androgen independent prostate cancer 1990–1999: a decade of progress?Ann Oncol2000; 11: 1523–1530.
2.
HudesG.R., ManolaJ., ConroyJ.Phase II study weekly Paclitaxel by 1-hour infusion plus reduced dose oral estramustine in metastatic hormone-refractory prostate carcinoma: a trial of the Eastern Cooperative Oncology Group.Proc Am Soc Clin Oncol2001; 20: 175a.
3.
HudesG.R., NathanF., KhaterC.Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.J Clin Oncol1997; 15: 3156–63.
4.
KellyW., ScherH., MazumdarM., VlanisM., SchwartzM., FossaS.Prostate Specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.J Clin Oncol1993, 11: 607–15.
5.
BubleyG., CarducciM., DahutW.Eligibility and response guidelines for phase II clinical trials in androgen indipendent prostate cancer: recommendations from the Prostate Specific Antigen Working Group.J Clin Oncol1999; 17: 3461–7.
6.
PicusJ., SchultzM.Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary resultsSemin Oncol Suppl1999; 26: 14.
7.
FriedlandD., CohenJ., MillerR.Jr., VoloshinM., GluckmanR., LemberskyB.A phase II trial of Docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.Semin Oncol1999; 26(suppl.): S19.
